CEFOTAXIME FOR INJECTION USP POWDER FOR SOLUTION

Země: Kanada

Jazyk: angličtina

Zdroj: Health Canada

Aktivní složka:

CEFOTAXIME (CEFOTAXIME SODIUM)

Dostupné s:

NOVOPHARM LIMITED

Dávkování:

500MG

Léková forma:

POWDER FOR SOLUTION

Složení:

CEFOTAXIME (CEFOTAXIME SODIUM) 500MG

Podání:

INTRAMUSCULAR

Jednotky v balení:

100

Druh předpisu:

Schedule G (CDSA IV)

Přehled produktů:

Active ingredient group (AIG) number: 0114953001

Stav Autorizace:

CANCELLED PRE MARKET

Datum autorizace:

2015-10-16

Charakteristika produktu

PRODUCT MONOGRAPH
CEFOTAXIME FOR INJECTION USP
(CEFOTAXIME SODIUM)
ANTIBIOTIC
Novopharm Limited
30 Novopharm Court
Toronto, ON
M1B 2K9
Control No. 141201
Date of Preparation: February 3, 1999
Date of Revision: December 2, 2010
2
PRODUCT MONOGRAPH
CEFOTAXIME FOR INJECTION USP
(CEFOTAXIME SODIUM)
500 MG, 1 G, AND 2 G CEFOTAXIME PER VIAL
THERAPEUTIC CLASSIFICATION
ANTIBIOTIC
ACTION AND CLINICAL PHARMACOLOGY
CEFOTAXIME for Injection USP (cefotaxime sodium) is a third generation
semisynthetic
cephalosporin antibiotic. Cefotaxime exerts its bactericidal action
through the inhibition of
bacterial cell wall synthesis. Cefotaxime is an aminothiazolyl
cephalosporin and contains an
aminothiazolyl-acetyl side chain, with an alpha-syn-methoximino group
at position 7 of the
cephalosporin nucleus. The aminothiazolyl side chain enhances
antibacterial activity, particularly
against Enterobacteriaceae, and the methoximino group imparts
stability against hydrolysis by
many β-lactamases.
INDICATIONS AND CLINICAL USE
TREATMENT
CEFOTAXIME for Injection USP (Cefotaxime sodium) may be indicated for
the treatment of
infections caused by susceptible strains of the designated
microorganisms in the diseases listed
below.
1.
Lower respiratory tract infections such as pneumonia and lung abscess
when caused by
_Streptococcus_
_pneumoniae_
, other streptococci (excluding enterococci, e.g.
_S. faecalis_
),
_Staphylococcus aureus_
(penicillinase and non-penicillinase producing),
_Escherichia coli_
,
_Haemophilus influenzae_
(including ampicillin resistant strains) and unspecified
_Klebsiella_
species.
2.
Urinary tract infections caused by
_Escherichia coli_
, unspecified
_Klebsiella_
species
(including
_K. pneumoniae_
),
_Proteus mirabilis, indole positive Proteus, Serratia_
_marcescens_
and
_Staphylococcus epidermidis_
. Also, uncomplicated gonorrhoea caused by
_N. gonorrhoeae_
including penicillin resistant strains.
3.
Bacteremia/Septicemia caused by
_Escherichia coli_
, unspecified
_Klebsiella_
strains and
_Serratia marcescens_
.
3
4.
Skin in